Chirag Jhaveri
A5008156163- Retinal Diseases and Treatments
- Retinal Imaging and Analysis
- Retinal and Optic Conditions
- Glaucoma and retinal disorders
- Retinal and Macular Surgery
- Ocular Diseases and Behçet’s Syndrome
- Intraocular Surgery and Lenses
- Retinal Development and Disorders
- Systemic Lupus Erythematosus Research
- Connexins and lens biology
- Peripheral Artery Disease Management
- Coronary Interventions and Diagnostics
- Central Venous Catheters and Hemodialysis
- Atherosclerosis and Cardiovascular Diseases
- Intraoperative Neuromonitoring and Anesthetic Effects
- Vascular Malformations Diagnosis and Treatment
- Healthcare and Venom Research
- Medical Imaging and Pathology Studies
- Traumatic Ocular and Foreign Body Injuries
- Ocular Surface and Contact Lens
- Bone health and treatments
- Ophthalmology and Visual Impairment Studies
- Angiogenesis and VEGF in Cancer
- IgG4-Related and Inflammatory Diseases
- Histiocytic Disorders and Treatments
Retina Consultants of Houston
2016-2024
Ahmedabad Civil Hospital
2022
The University of Texas at Austin
2019-2021
Retina Research Foundation
2019
Ochsner Medical Center
2012
Intravitreous injections of antivascular endothelial growth factor agents are effective for treating diabetic macular edema (DME) involving the center macula (center-involved DME [CI-DME]) with visual acuity impairment (20/32 or worse). The best approach to patients CI-DME and good (20/25 better) is unknown.To compare vision loss at 2 years among eyes initially managed aflibercept, laser photocoagulation, observation.Randomized clinical trial conducted 91 US Canadian sites 702 adults type 1...
PurposeThe phase 2 BOULEVARD trial compared safety and efficacy of faricimab, a novel bispecific antibody targeting angiopoietin-2 vascular endothelial growth factor-A (VEGF-A), with ranibizumab in patients diabetic macular edema (DME).DesignThe (ClinicalTrials.gov identifier, NCT02699450) was prospective, randomized, active comparator-controlled, double-masked, multicenter, study conducted at 59 sites the United States.ParticipantsThe enrolled 18 years age or older center-involving DME,...
<h3>Importance</h3> Vitreous hemorrhage from proliferative diabetic retinopathy can cause loss of vision. The best management approach is unknown. <h3>Objective</h3> To compare initial treatment with intravitreous aflibercept vs vitrectomy panretinal photocoagulation for vitreous retinopathy. <h3>Design, Setting, and Participants</h3> Randomized clinical trial at 39 DRCR Retina Network sites in the US Canada including 205 adults vison due to who were enrolled November 2016 December 2017....
In eyes with diabetic macular edema, the relative efficacy of administering aflibercept monotherapy as compared bevacizumab first a switch to if eye condition does not improve sufficiently (a form step therapy) is unclear.At 54 clinical sites, we randomly assigned in adults who had edema involving center and visual-acuity letter score 24 69 (on scale from 0 100, higher scores indicating better visual acuity; Snellen equivalent, 20/320 20/50) receive either 2.0 mg intravitreous or 1.25...
<h3>Importance</h3> The follow-up schedule for individuals with eyes treated anti–vascular endothelial growth factor agents proliferative diabetic retinopathy (PDR) requires that patients return frequently monitoring and repeated treatment. likelihood a patient will comply should be consideration in choosing treatment approach. <h3>Objective</h3> To describe completion of scheduled examinations among participants assigned to intravitreous injections ranibizumab PDR multicenter randomized...
Importance The DRCR Retina Network Protocol AC showed no significant difference in visual acuity outcomes over 2 years between treatment with aflibercept monotherapy and bevacizumab first switching to for suboptimal response treating diabetic macular edema (DME). Understanding the estimated cost cost-effectiveness of these approaches is important. Objective To evaluate vs bevacizumab-first strategies DME treatment. Design, Setting, Participants This economic evaluation was a preplanned...
To investigate whether anti-vascular endothelial growth factor (anti-VEGF) for diabetic macular edema or proliferative retinopathy (PDR) increases the risk of traction retinal detachment (TRD) among eyes with PDR.Pooled analysis PDR from Protocols I, J, N, S, T Early Treatment Diabetic Retinopathy Study level ≥61 (prompt vitrectomy was not planned) randomly assigned to control group (laser photocoagulation, sham, intravitreal saline; 396 eyes) anti-VEGF (487 eyes). The primary outcome...
PURPOSE: To describe the Port Delivery System with ranibizumab refill-exchange procedure. METHODS: Procedure based on clinical trial program in patients retinal diseases. RESULTS: The procedure is performed under topical anesthesia and strict aseptic conditions. Supplemental task lighting magnification are recommended throughout Ranibizumab aseptically transferred from vial filter needle air removed syringe. then replaced refill needle; any remaining syringe plunger advanced to 0.1-mL mark....
Abstract Purpose To evaluate the effects of oral emixustat hydrochloride on pro-angiogenic and inflammatory cytokines in aqueous humor, as well other ophthalmic parameters, subjects with proliferative diabetic retinopathy (PDR). Methods Twenty-three patients PDR, or without macular edema (DME), were assigned to placebo daily doses ranging from 5 40 mg over a step-up titration period, for 84 days. The main outcome measures included levels IL-1β, IL-6, IL-8, TGFβ-1, VEGF humor. Results Seven...
The aim of this study was to determine associations between early residual fluid (ERF)-free status and improved long-term visual outcomes.This a retrospective clinical cohort from post hoc analysis 2 phase III trials' data.Independent treatment allocation, patients the multicenter, prospective, randomized, double-masked HAWK HARRIER trials who received either brolucizumab 6 mg or aflibercept were split into cohorts depending on presence absence ERF at week 12. In addition, similar analyses...
Purpose: To determine the association between central subfield thickness (CST) variability and visual outcomes in eyes with neovascular age-related macular degeneration treated anti–vascular endothelial growth factor therapies. Methods: In this post hoc, treatment-agnostic analysis, patients (N = 1,752) were grouped into quartiles of increasing CST variation. The best-corrected acuity was measured from baseline, or end loading phase, until study using a multilevel modeling for...
Frequent steroid drops represent a challenge in patient compliance. This study evaluated the safety and efficacy of 5 minute topical dexamethasone sodium phosphate-Visulex (DSP-Visulex) treatment regimen (two applications on first week then weekly after) compared to daily prednisolone acetate 1% (PA) for noninfectious anterior uveitis.Forty-four patients were randomized 8% DSP-Visulex with placebo eye (8% group, n = 14), 15% (15% 15), or Vehicle-Visulex PA (PA 15). Patients received Visulex...
Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA Ophthalmology HomeNew OnlineCurrent IssueFor Authors Podcast Journals Network Open Cardiology Dermatology Health Forum Internal Medicine Neurology Oncology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) JN Learning / CMESubscribeJobsInstitutions LibrariansReprints Permissions Terms Use Privacy Accessibility...
To evaluate the safety and efficacy of BI 1467335 in patients with non-proliferative diabetic retinopathy (NPDR).
Silicone oil is a commonly used tamponade agent. We report the rare complication of patient who presented with silicone in suprachoroidal space following retinal detachment repair. The was subsequently removed without any long-term complications. [ Ophthalmic Surg Lasers Imaging Retina. 2013;44:284–286.]
Jhaveri, Chirag D.; Jampol, Lee M.; Van Gelder, Russell N.; Cunningham, Emmett T JrEditor(s): Richard McDonald, H. Author Information